This product is isolated and purified from the herbs of Piper puberulilimbum
1,7,7-Trimethylbicyclo[2.2.1]hept-2-yl 4-hydroxybenzoate/Benzoic acid, 4-hydroxy-, 1,7,7-trimethylbicyclo[2.2.1]hept-2-yl ester
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
381.6±15.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:62356-47-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
Obesity and its associated non-alcoholic fatty liver disease (NAFLD) have become epidemic medical problems worldwide; however, the current available therapeutic options are limited. Farnesoid X receptor (FXR) has recently emerged as an attractive target for obesity treatment. Here we demonstrate that isotschimgine (ITG), a constituent in genus Ferula, as a novel FXR agonist with anti-obesity and anti-hepatic steatosis effects. The results showed that ITG activated the FXR transactivity and bound with the ligand binding dormain (LBD) of FXR with gene reporter assays and AlphaScreen assays. In high-fat diet-induced obese (DIO) mice, ITG lowered body weight and fat mass, improved insulin resistance and hepatic steatosis. Mechanistic studies showed that ITG altered the expression levels of FXR downstream genes, lipid synthesis and energy metabolism genes in the liver of mice. Our findings suggest that ITG is a novel FXR agonist and may be a potential therapeutic choice for obesity associated with NAFLD.
Copyright © 2019 Elsevier Inc. All rights reserved.
Farnesoid X receptor; Isotschimgine; Non-alcoholic fatty liver disease; Obesity
Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice.
Li Y1, Chen H1, Ke Z1, Huang J2, Huang L2, Yang B1, Fan S3, Huang C4.
2020 Jan 15